Treatment for recurrent CD19 positive adult B-cell cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of GT719 Injection in patients with relapsed or refractory CD19 positive adult B-cell malignancies, specifically B-cell non-Hodgkin lymphoma and B-acute lymphoblastic leukemia. It is a single-arm, open-label study that includes both dose escalation and expansion phases, aiming to enroll a total of 34 subjects. Participants will be monitored for cellular pharmacokinetics and overall treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol.

   \-
2. Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.

   \-
3. CD19 positivity confirmed by flow cytometry and/or histopathology.

Exclusion Criteria:

1. Primary immunodeficiency.

   \-
2. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.

   \-
3. Any medical condition that may interfere with the evaluation of the safety or effectiveness of research and treatment;

Where it's running

• Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Dehui Zou
• Email: zoudehui@ihcams.ac.cn
• Phone: +8613602100955

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GT719 universal cell injection for adults with relapsed or refractory CD19-positive B-cell cancers

  This trial will test whether GT719, a universal CD19-targeting cell injection, is safe and can induce remissions in adults with relapsed or refractory CD19-positive B-cell lymphoma or B-cell acute lymphoblastic leukemia.

  Recruiting Early Phase 1 Grit Biotechnology · Ganzhou, Jiangxi · NCT07131254

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

• See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging

  Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT07292272

• Using Fourth-Generation CAR-T to treat blood cancers

  This study is testing a new type of CAR-T therapy to see if it can safely help people with blood cancers like Multiple Myeloma and B-cell Lymphoma.

  Recruiting Phase 1 The Third Affiliated Hospital of Southern Medical University · Guangzhou, Guangdong · NCT06758713

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.